Cencora, Inc.’s $1.8 Billion Registered Senior Notes Offering

Cravath represented the underwriters in connection with the $3 billion registered senior notes offering of Cencora, Inc., a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. Proceeds of the offering were used to repay, in full, the term loan facility used to finance Cencora, Inc's acquisition of OneOncology. The transaction closed on February 13, 2026.

Cravath represented the administrative agent, joint lead arrangers and joint bookrunners in connection with $5.5 billion of credit facilities made available to Cencora, Inc., as part of the financing transactions undertaken in connection with its acquisition of OneOncology, a physician‑led national platform empowering independent medical specialty practices rooted in oncology. Cencora, Inc. is a leading global pharmaceutical sourcing and distribution services company. The credit facilities consisted of a $1.5 billion term loan facility, a $3.0 billion term loan facility and a $1.0 billion commitment increase under an existing revolving credit facility. The transaction closed on January 12, 2026.

Cravath represented the administrative agent, joint lead arranger and joint bookrunner in connection with a $4.5 billion revolving credit facility made available to Cencora, Inc., a leading global pharmaceutical sourcing and distribution services company, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The transaction closed on June 4, 2025.

Cravath represented the underwriters in connection with the €1 billion registered senior notes offering of Cencora, Inc., a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. The transaction closed on May 22, 2025.